Why the study?
The multifunctional receptor LRP1 controls PDGF receptor-beta expression, activity, and trafficking in vascular smooth muscle cells and is required for TGFbeta1-mediated inhibition of cell proliferation, prompting investigation of VSMC LRP1 loss in vivo.
Does rosiglitazone reverse the Marfan-like phenotype and reduce atherosclerosis in smLRP(-) animal models?
Does rosiglitazone reverse the Marfan-like phenotype and reduce atherosclerosis in smLRP(-) animal models?
LRP1 functions as an atheroprotective integrator of TGFβ and PDGF signals, and its deficiency in VSMCs causes a Marfan-like syndrome that can be reversed by rosiglitazone.
Answers are grounded in this paper and cite their sources.
Rosiglitazone should not alter clinical management of Marfan syndrome or atherosclerosis; leaves open translation of LRP1-TGFβ modulation to human disease.
Background The multifunctional receptor LRP1 controls expression, activity and trafficking of the PDGF receptor-β in vascular smooth muscle cells (VSMC). LRP1 is also a receptor for TGFβ1 and is required for TGFβ mediated inhibition of cell proliferation. Methods and Principal Findings We show that loss of LRP1 in VSMC (smLRP−) in vivo results in a Marfan-like syndrome with nuclear accumulation of phosphorylated Smad2/3, disruption of elastic layers, tortuous aorta, and increased expression of the TGFβ target genes thrombospondin-1 (TSP1) and PDGFRβ in the vascular wall. Treatment of smLRP1− animals with the PPARγ agonist rosiglitazone abolished nuclear pSmad accumulation, reversed the Marfan-like phenotype, and markedly reduced smooth muscle proliferation, fibrosis and atherosclerosis independent of plasma cholesterol levels. Conclusions and Significance Our findings are consistent with an activation of TGFβ signals in the LRP1-deficient vascular wall. LRP1 may function as an integrator of proliferative and anti-proliferative signals that control physiological mechanisms common to the pathogenesis of Marfan syndrome and atherosclerosis, and this is essential for maintaining vascular wall integrity.
No takes yet. Share an insight, caveat, or question.
Boucher et al. (2007) studied Atherosclerosis and Marfan-like syndrome (preclinical mouse model) (n=40). Rosiglitazone vs. Untreated high-fat/high-cholesterol diet was evaluated on Aortic atherosclerotic lesion size (p=<0.05).
Synapse has enriched 10 related papers. Consider them for comparative context: